A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
Categories (click each to see list of all clinical trials associated with that category): Thoracic (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Abughanimeh, Omar
Eligibility: ASTRIDE HLX10-005-SCLC301-E Subject Eligibility Worksheet_v6.0_04Apr2024.docx
Summary
To compare the efficacy of HLX10 plus chemotherapy versus atezolizumab plus chemotherapy in US patients with previously untreated ES-SCLC
Secondary Objective:
To evaluate the efficacy of HLX10 plus chemotherapy in US patients with previously untreated ES-SCLC
To evaluate the clinical safety, the pharmacokinetics and immunogenicity of HLX10 in combination with chemotherapy in US patients with previously untreated ES-SCLC